Formulation, Optimization, and Predictive Modelling of Naratriptan Hydrochloride Dry Powder Inhaler for Enhanced Pulmonary Delivery in Migraine Management
EJPPS - European Journal of Parenteral and Pharmaceutical Sciences · 2026-07-02
DOI: 10.37521/ejpps31205 ↗At a glance
Journal article in EJPPS - European Journal of Parenteral and Pharmaceutical Sciences, published online on 2026-07-02. Written by Milind Thosar and 2 co-authors. 23 references.
Abstract (original language)
Naratriptan Hydrochloride, a selective 5-HT1B/1D receptor agonist, is clinically used for the acute treatment of migraines. Despite its effectiveness, conventional oral administration suffers from delayed onset, gastric stasis during migraine attacks, and extensive first-pass metabolism. To overcome these drawbacks, a dry powder inhaler (DPI) formulation was developed to achieve rapid systemic drug delivery through pulmonary absorption. The DPI formulation was optimized using Box-Behnken Design (BBD) with Inhalac 230, Inhalac 400, and magnesium stearate as formulation variables. Preformulation studies such as FTIR and XRD confirmed drug purity, crystallinity, and compatibility with excipients. The optimized batch displayed excellent flowability (angle of repose: 31.25°), high fine particle fraction (FPF: 35.90%), and satisfactory in-vitro drug release (67.25%). Scanning Electron Microscopy (SEM) confirmed uniform morphology and efficient drug-carrier adhesion. In-vitro diffusion using Franz diffusion cells and ex-vivo permeation studies using goat lung tissue demonstrated improved drug permeability and sustained release behaviour. A Multiple Linear Regression (MLR) model was established using formulation and physicochemical descriptors to predict lung deposition (%FPF), yielding a predictive R² value of 0.74. The model highlighted significant variables influencing aerosol performance, such as MMAD, GSD, and carrier size. This study successfully presents the first DPI formulation of Naratriptan HCl, addressing the unmet need for non-oral, rapid-acting migraine therapies. It demonstrates enhanced drug delivery, improved patient compliance, and potential for early intervention during migraine episodes. The combined experimental and modelling approach supports the feasibility of Naratriptan DPI for clinical translation. Keywords: Naratriptan Hydrochloride, Dry Powder Inhaler, Pulmonary Drug Delivery, Migraine, Box-Behnken Design, Fine Particle Fraction, Lung Deposition, Multiple Linear Regression
Cite
APA
Thosar, M., Zinzuvadiya, M., & Savaniya, A. (2026). Formulation, Optimization, and Predictive Modelling of Naratriptan Hydrochloride Dry Powder Inhaler for Enhanced Pulmonary Delivery in Migraine Management. EJPPS - European Journal of Parenteral and Pharmaceutical Sciences. https://doi.org/10.37521/ejpps31205
Vancouver
Thosar M, Zinzuvadiya M, Savaniya A. Formulation, Optimization, and Predictive Modelling of Naratriptan Hydrochloride Dry Powder Inhaler for Enhanced Pulmonary Delivery in Migraine Management. EJPPS - European Journal of Parenteral and Pharmaceutical Sciences. 2026. doi:10.37521/ejpps31205
BibTeX
@article{Thosar2026,
author = {Thosar, Milind and Zinzuvadiya, Madhav and Savaniya, Ajay},
title = {Formulation, Optimization, and Predictive Modelling of Naratriptan Hydrochloride Dry Powder Inhaler for Enhanced Pulmonary Delivery in Migraine Management},
journal = {EJPPS - European Journal of Parenteral and Pharmaceutical Sciences},
year = {2026},
doi = {10.37521/ejpps31205}
}
EUVIMED